Vivek Kumar Singh

Vivek Kumar Singh

Auto-generated profile, based on publicly available information

Vivek Kumar Singh

Pondicherry University

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2015 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YKYi-Yu Ke
Yi-Yu Ke
VSVivek Kumar Singh
Vivek Kumar Singh
MCMohane Coumar
Mohane Coumar
YHYung Chang Hsu
Yung Chang Hsu
WWWen-Chieh Wang
Wen-Chieh Wang
HHHsing-Pang Hsieh
Hsing-Pang Hsieh
The inhibition of FMS-like tyrosine kinase 3 (FLT3) activity using small-molecule inhibitors has emerged as a target-based alternative to traditional chemotherapy for the treatment of acute myeloid leukemia (AML). In this study, we report the use of structure-based virtual screening (SBVS), a computer-aided drug design technique for the identification of new chemotypes for FLT3 inhibition. For this purpose, homology modeling (HM) of the DFG-in FLT3 structure was carried using two template structures, including PDB ID: 1RJB (DFG-out FLT3 kinase domain) and PDB ID: 3LCD (DFG-in CSF-1 kinase domain). The modeled structure was able to correctly identify known DFG-in (SU11248, CEP-701 and PKC-412) and DFG-out (sorafenib, ABT-869 and AC220) FLT3 inhibitors, in docking studies. The modeled structure was then used to carry out SBVS of an HTS library of 125,000 compounds. The top scoring 97 compounds were tested for FLT3 kinase inhibition and two hits (BPR056, IC50 = 2.3 and BPR080, IC50 = 10.7 μM) were identified. Molecular dynamics simulation and density functional theory calculation suggest that BPR056 (MW: 325.32; cLogP: 2.48) interacted with FLT3 in a stable manner and could be chemically optimized to realize a drug-like lead in the future.

1 March 2014 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
KMKumaravel Mohankumar
Kumaravel Mohankumar
SPSankar Pajaniradje
Sankar Pajaniradje
SSSubhashree Sridharan
Subhashree Sridharan
VSVivek Kumar Singh
Vivek Kumar Singh
LRLarance Ronsard
Larance Ronsard
RRRukkumani Rajagopalan
Rukkumani Rajagopalan

26 October 2014 in Journal of Computer-Aided Molecular Design
Verified
Journal Article
Closed access
PDF file
SSSailu Sarvagalla
Sailu Sarvagalla
VSVivek Kumar Singh
Vivek Kumar Singh
YKYi-Yu Ke
Yi-Yu Ke
HSHui-Yi Shiao
Hui-Yi Shiao
WLWen-Hsing Lin
Wen-Hsing Lin
MCMohane Coumar
Mohane Coumar

1 December 2014 in Cellular Oncology
Verified
Journal Article
Closed access
PDF file
KMKumaravel Mohankumar
Kumaravel Mohankumar
SPSankar Pajaniradje
Sankar Pajaniradje
SSSubhashree Sridharan
Subhashree Sridharan
VSVivek Kumar Singh
Vivek Kumar Singh
LRLarance Ronsard
Larance Ronsard
RRRukkumani Rajagopalan
Rukkumani Rajagopalan

11 June 2016 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
VSVivek Kumar Singh
Vivek Kumar Singh
HCHsin-Huei Chang
Hsin-Huei Chang
CKChing-Chuan Kuo
Ching-Chuan Kuo
HSHui-Yi Shiao
Hui-Yi Shiao
HHHsing-Pang Hsieh
Hsing-Pang Hsieh
MCMohane Coumar
Mohane Coumar
Chronic myeloid leukemia (CML) is caused by chromosomal rearrangement resulting in the expression of Bcr-Abl fusion protein with deregulated Abl tyrosine kinase activity. Approved drugs – imatinib, dasatinib, nilotinib, and ponatinib – target the ATP-binding site of Abl kinase. Even though these drugs are initially effective, long-term usefulness is limited by the development of resistance. To overcome this problem, targeting the allosteric site of Abl kinase, which is remote from the ATP-binding site is found to be a useful strategy. In this study, structure-based and ligand-based virtual screening methods were applied to narrow down possible drugs (from DrugBank database) that could target the allosteric site of Abl kinase. Detailed investigations of the selected drugs in the allosteric site of Abl kinase, using molecular dynamics and steered molecular dynamics simulation shows that gefitinib, an EGFR inhibitor approved for the treatment of lung cancer, could bind effectively to the allosteric site of Bcr-Abl. More interestingly, gefitinib was found to enhance the ability of imatinib to bind at the ATP-binding site of Bcr-Abl kinase. Based on the in silico findings, gefitinib was tested in combination with imatinib in K562 CML cell line using MTT cell proliferation assay and found to have a synergistic antiproliferative activity. Further detailed mechanistic study could help to unravel the full potential of imatinib – gefitinib combination for the treatment of CML.

11 July 2026 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
AKAafreen Khan
Aafreen Khan
SGSmeeta Gajendra
Smeeta Gajendra
SRSandeep Rai
Sandeep Rai
DTDeepshi Thakral
Deepshi Thakral
VSVivek Kumar Singh
Vivek Kumar Singh
RGRitu Gupta
Ritu Gupta